Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Compass claims a pivotal win with tovecimig
A biliary tract cancer trial hits on response rate, but survival data will be key.
